Evidence map›Paper›PMID 30087106›Full record

Trial reportBlood advances2018

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Shernan G Holtan, Todd E DeFor, Angela Panoskaltsis-Mortari, Nandita Khera, John E Levine, Mary E D Flowers, Stephanie J Lee, Yoshihiro Inamoto, George L Chen, Sebastian Mayer and 27 more

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Radiology. Imaging cancer · 2025
    Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  19. Acute GVHD: think before you treat.Hematology. American Society of Hematology. Education Program · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Shernan G HoltanHematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
Todd E DeForHematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
Angela Panoskaltsis-MortariHematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
Nandita KheraMayo Clinic, Phoenix, AZ.
John E LevineBlood and Marrow Transplantation Program, The Icahn School of Medicine at Mount Sinai, New York, NY.
Mary E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Stephanie J LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Yoshihiro InamotoDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
George L ChenDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
Sebastian MayerDepartment of Medicine, Weill Cornell Medical Center, New York, NY.
Mukta AroraHematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
Jeanne PalmerMayo Clinic, Phoenix, AZ.
Corey S CutlerHematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Sally AraiDivision of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA.
Aleksandr LazaryanHematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
Laura F NewellCenter for Hematologic Malignancies, Oregon Health and Science University, Portland, OR.
Madan H JagasiaDivision of Hematology/Oncology, Stem Cell Transplantation, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Iskra PusicMedical Oncology, Washington University Medical Center, St. Louis, MO.
William A WoodLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
Anne S RenteriaBlood and Marrow Transplantation Program, The Icahn School of Medicine at Mount Sinai, New York, NY.
Gregory YanikBlood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI.
William J HoganBlood and Marrow Transplantation Program, Mayo Clinic, Rochester, MN.
Elizabeth HexnerAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Francis AyukDepartment of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Germany.
Ernst HollerBlood and Marrow Transplantation Program, University of Regensburg, Regensburg, Germany.
Udomsak BunworasateBlood and Marrow Transplantation Program, Chulalongkorn University, Bangkok, Thailand.
Yvonne A EfeberaBlood and Marrow Transplantation Program, The Ohio State University, Columbus, OH.
James L M FerraraBlood and Marrow Transplantation Program, The Icahn School of Medicine at Mount Sinai, New York, NY.
Joseph PidalaBlood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Alan HowardNational Marrow Donor Program, Minneapolis, MN.
Juan WuThe EMMES Corporation, Rockville, MD.
Javier Bolaños-MeadeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; and.
Vincent HoDivision of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA.
Amin AlousiMD Anderson Cancer Center, Houston, TX.
Bruce R BlazarHematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
Daniel J WeisdorfHematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
Margaret L MacMillanHematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
TUMOR VACCINES AND BONE MARROW TRANSPLANTATIONP01CA039542 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAVAN REDDY · 1985 to 2026
$47.9M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
TUMOR VACCINESP01CA015396 · NCI · JOHNS HOPKINS UNIVERSITY · PI HESS, ALLAN D · 1985 to 2016
$38.1M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Improving Outcomes Assessment in Chronic GVHDR01CA118953 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2011 to 2025
$8.3M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Training and Career Development CoreU54CA163438 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2011 to 2014
$3.7M
Improving Outcomes Assessment in Chronic GVHDU01CA118953 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2007 to 2010
$3.1M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P01 CA015396NCI NIH HHS P01 CA039542NCI NIH HHS P01 CA065493NCI NIH HHS R01 CA118953NCI NIH HHS U01 CA118953NCI NIH HHS U24 CA076518NCI NIH HHS U54 CA163438NHLBI NIH HHS R01 HL118979NHLBI NIH HHS U01 HL069310NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U10 HL069310NHLBI NIH HHS U10 HL069330NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069249NHLBI NIH HHS UG1 HL069278NHLBI NIH HHS UG1 HL069290NHLBI NIH HHS UG1 HL069330NHLBI NIH HHS UG1 HL109137NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

Amphiregulin (AREG) is an epidermal growth factor receptor ligand that can restore integrity to damaged intestinal mucosa in murine models of acute graft-versus-host disease (aGVHD). We previously reported that circulating AREG is elevated in late-onset aGVHD (occurring after 100 days posttransplant), but its clinical relevance in the context of aGVHD risk is unknown. We measured AREG in 251 aGVHD onset blood samples from Blood and Marrow Clinical Trials Network (BMT CTN) primary treatment trials and determined their association with GVHD severity, day 28 complete or partial response (CR/PR) to first-line therapy, overall survival (OS), and nonrelapse mortality (NRM). Every doubling of plasma AREG was associated with a 33% decrease in the odds of day 28 CR/PR (odds ratio [OR], 0.67;

Indexed as

AdolescentAdultAmphiregulinDisease-Free SurvivalFemaleGraft vs Host DiseaseHumansMaleMiddle AgedMinnesotaRisk AssessmentSeverity of Illness IndexSurvival RateAmphiregulinAREG protein, human

Identifiers

PMID30087106
PMCPMC6093743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.